Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL686092 | 0.98 | TSHR (0.37) | TSHR | |
| SCHEMBL684980 | 0.98 | TSHR (0.37) | TSHR | |
| SCHEMBL684954 | 0.98 | TSHR (0.37) | TSHR | |
| SCHEMBL673360 | 0.92 | TSHR (0.41) | TSHR | |
| Acrylic Acid SCHEMBL8364683 | 0.87 | TSHR (0.37) | TSHR | |
| SCHEMBL8106024 | 0.84 | HCAR2 (0.33) | — | |
| SCHEMBL8102011 | 0.82 | HCAR2 (0.32) | — | |
| Methacrylic Acid SCHEMBL5177816 | 0.82 | TSHR (0.34) | TSHR | |
| SCHEMBL4399278 | 0.82 | TSHR (0.38) | TSHR | |
| SCHEMBL4807624 | 0.82 | TSHR (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565554-B2 | Dual-phase zwitterionic monomers | KUNZLER BIOMEDICAL LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12510690-B2 | Ophthalmic devices | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-12-30 | — | — | US | disclosed |
| US-20250326873-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371519-B2 | Dual-phase zwitterionic monomers | Envision Biomedical LLC (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025094825-A1 | HETEROPOLYOXOMETALATE HAVING MODIFIED LACUNARY SITE, OR MIXTURE THEREOF | 東京応化工業株式会社 | 2025-05-08 | — | — | WO | disclosed |
| US-20250092174-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4483218-A1 | OPHTHALMIC DEVICES | Bausch + Lomb Ireland Limited (IE) | 2025-01-01 | — | — | EP | disclosed |
| US-12054590-B2 | Hydrogel polymers | GL CHEMTEC VISION INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-11905351-B2 | Silicone hydrogel materials | Envision Biomedical LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240026049-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | Envision Biomedical LLC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-0338656-B1 | Polymeric silicone-based materials with high oxygen permeability | BAUSCH & LOMB (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0328340-B1 | HYDROPHILIC OXYGEN PERMEABLE POLYMERS | BAUSCH & LOMB INCORPORATED (US) | 1993-03-31 | — | — | EP | disclosed |
| US-4910277-A | Blend of polysiloxane and an interior wetting agent | BAUSCH & LOMB INCORPORATED | 1990-03-20 | — | — | US | disclosed |
| EP-0338656-A2 | Polymeric silicone-based materials with high oxygen permeability | BAUSCH & LOMB INCORPORATED (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4870145-A | Process for preparing polymeric beads | BAUSCH & LOMB INCORPORATED (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0328340-A2 | Hydrophilic oxygen permeable polymers | BAUSCH & LOMB INCORPORATED (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0124017-B1 | POLYSILOXANE COMPOSITION WITH IMPROVED SURFACE WETTING CHARACTERISTICS AND BIOMEDICAL DEVICES MADE THEREOF | BAUSCH & LOMB INCORPORATED (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4810764-A | CONTACT LENSES | BAUSCH & LOMB INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| US-4652622-A | CONTACT LENSES | BAUSCH & LOMB INCORPORATED (US) | 1987-03-24 | — | — | US | disclosed |
| US-4495361-A | N-ALKENOYL TRIALKYSILYL AMINATE | BAUSCH & LOMB INCORPORATED (US) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092174-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885 |
| US-12510690-B2 | Ophthalmic devices | AXL, SLCO1B1, SLCO1B3 | TSHR 1414/4885 |
| US-12565554-B2 | Dual-phase zwitterionic monomers | HAO2, CRYZ, CRYAA | TSHR 1764/4885 |
| US-20250326873-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885 |
| US-20240026049-A1 | DUAL-PHASE ZWITTERIONIC MONOMERS | RAD1, RAD51, VCL | TSHR 3440/4885 |
| US-12371519-B2 | Dual-phase zwitterionic monomers | RAD1, RAD51, VCL | TSHR 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.